IMPLEMENTATION OF PHARMACOGENOMICS INTO CLINICAL CAREIMPLEMENTATION OF PHARMACOGENOMICS INTO CLINICAL CARE

Donald K. Baker, PharmD, MBA — St. Jude Children’s Research Hospital // Development of PGx Rules and Clinical Decision Support Tools

CONFERENCE SPEAKERS AND TOPICS

Jeffrey Bishop, PharmD, MS, BCPP, FCCP — University of Minnesota College of Pharmacy // Evidence for Implementation of PGx in Psychiatry and Emerging Areas

Jacob Brown, PharmD, MS — University of Minnesota College of Pharmacy // A Behind-the-Scenes Look at the Evidence Review Process for Drug-Gene Pairs

Pedro J. Caraballo, MD — Mayo Clinic // Creating a Multidisciplinary Model to Implement PGx

Kelly E. Caudle, PharmD, PhD, BCPS — St. Jude Children’s Research Hospital // CPIC and Emerging Regulatory Issues from the FDA

Elise Durgin, PharmD — Children’s Minnesota // Providing PGx-Guided Care in the Absence of Clinical Guidelines

Joel Farley, BS, PhD, FAPhA — University of Minnesota College of Pharmacy // The Evidence for Cost Effectiveness and Quality Improvement of PGx Services

Andrea Gaedigk, MS, PhD — University of Missouri-KC School of Medicine and Children’s Mercy Hospital & Clinics // The PharmVar Consortium and Standardization of Pharmacogene Variation to Facilitate Interpretation of Test Results

David Gregornik, BS, PharmD, BCOP — Children’s Minnesota // Implementation of PGx at Children’s Minnesota

Cyrine Haidar, PharmD, BCPS, BCOP — St. Jude Children’s Research Hospital // Implementation of PGx at St. Jude Children’s Research Hospital

Pamala Jacobson, PharmD, FCCP — University of Minnesota College of Pharmacy // Evidence for Implementation of PGx in Transplantation and Future Directions

Jason H. Karnes, PharmD, PhD, BCPS, FAHA — University of Arizona College of Pharmacy // Evidence for Implementation of PGx for Hypersensitivity Reactions and Future Directions

Eric T. Matey, PharmD, BCACP, MBA — Mayo Clinic // Return of PGx Results to the Patient via E-Consult

Minoli Perera, PharmD, PhD — Northwestern University Feinberg School of Medicine // Special Considerations for Implementation of PGx in Minority Populations

Victoria Pratt, PhD, FACMG — Indiana University School of Medicine // Not All PGx Assays are the Same: Selection of a PGx Assay That’s Right for Your Patients

KEYNOTE SPEAKERLarisa H. Cavallari, PharmD, BCPS, FCCP — University of Florida College of Pharmacy // The Future of Pharmacogenomics

IMPLEMENTATION OF PHARMACOGENOMICS INTO CLINICAL CAREIMPLEMENTATION OF PHARMACOGENOMICS INTO CLINICAL CARE

April Schultz, PharmD — Sanford Health // Implementation of PGx at Sanford Health

Valentina Shakhnovich, MD — University of Missouri-Kansas City School of Medicine and Children’s Mercy Hospital & Clinics // Evidence for Implementation of PGx for Proton Pump Inhibitors

D. Max Smith, PharmD, BCPS — MedStar Health // Evidence for Implementation of PGx for Opioids

Todd D. Sorensen, PharmD, FAPhA, FCCP — University of Minnesota College of Pharmacy // Pathway for Implementation of a Healthcare Innovation: PGx

Laura B. Ramsey, PhD — Cincinnati Children’s Hospital Medical Center // Evidence for Implementation of PGx in Pediatrics and Future Directions

Robert J. Straka, PharmD, FCCP — University of Minnesota College of Pharmacy // How to Navigate Drug-Drug Interactions in the Patient with Pharmacogenomic Variants: PGx Phenoconversion

Sony Tuteja, PharmD, MS, BCPS, FAHA — University of Pennsylvania Perelman School of Medicine // Evidence for Implementation of PGx in Cardiovascular and Emerging Areas

Sara L. Van Driest, MD, PhD — Vanderbilt University Medical Center // Implementation of PGx at Vanderbilt University

R E G I S T E R T O D A Y A T Z . U M N . E D U / P G X 2 0 2 0